News
Generic ABSORICA® added to US portfolio
29 Sep 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of isotretinoin capsules, 10 mg, 20 mg, 30 mg and 40 mg in the United States.
Learn more
FDA Approves Lexette® for Adolescent Plaque Psoriasis
22 Sep 2021
Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents.
Learn more
2021 Full Year Results Media Release
27 Aug 2021
2021 Full Year Results Media Release
Learn more
Mayne Pharma Board Renewal and New Chairman
26 Aug 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella, a US resident, will be appointed Chairman with effect from 30 September 2021.
Learn more
Class action proceeding
3 Aug 2021
Mayne Pharma Group Limited (ASX: MYX) has been served with a class action proceeding against Mayne Pharma in the Supreme Court of Victoria.
Learn more
Mayne Pharma expands Australian dermatology portfolio
21 Jun 2021
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has licensed the Australian rights to SOLARAZE®
Learn more
Nextstellis® Oral Contraceptive Now Available in the United States
21 Jun 2021
US commercial launch of NEXTSTELLIS® a new oral contraceptive with a novel estrogen.
Learn more
Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published
27 May 2021
NEXTSTELLIS® has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA)
Learn more
FDA approval of novel oral contraceptive NEXTSTELLIS®
16 Apr 2021
US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive NEXTSTELLIS®
Learn more